Coya Therapeutics financials
$5.03+1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $243.7K | $251.1K | $4.0M | $3.6M | $163.6K | $257.9K | $2.0K | $0.00 | $3.4M | $126.8K | $6.0M | $0.00 |
| Gross profit | $243.7K | $251.1K | $4.0M | $3.6M | $163.6K | $257.9K | $2.0K | $0.00 | $3.4M | $126.8K | $6.0M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$7.0M | -$7.6M | -$6.0M | -$2.4M | -$6.4M | -$7.7M | -$4.1M | -$4.5M | -$3.2M | -$5.5M | $1.8M | -$3.6M |
| Net income | -$6.6M | -$7.2M | -$5.7M | -$2.1M | -$6.1M | -$7.3M | -$2.9M | -$4.0M | -$2.9M | -$5.1M | $1.3M | -$3.4M |
| Net margin | −2723.4% | −2869.6% | −144.2% | −59.4% | −3725.2% | −2833.4% | −149373.8% | — | −84.4% | −3983.0% | 21.1% | — |
| Diluted EPS | $-0.28 | $-0.32 | $-0.34 | $-0.13 | $-0.36 | $-0.44 | $-0.18 | $-0.26 | $-0.19 | $-0.35 | $0.11 | $-0.34 |
| EBITDA | -$7.0M | -$7.6M | -$6.0M | -$2.4M | -$6.4M | -$7.7M | -$4.1M | -$4.4M | -$3.2M | -$5.5M | $1.8M | -$3.6M |
| Operating cash flow | -$7.4M | -$6.2M | -$1.0M | -$1.1M | -$5.8M | -$2.8M | -$2.4M | -$5.5M | -$4.6M | $2.1M | -$2.2M | -$2.2M |
| Free cash flow | -$7.4M | -$6.2M | -$1.0M | -$1.1M | -$5.8M | -$2.8M | -$2.4M | -$5.5M | -$4.6M | $2.1M | -$2.6M | -$2.6M |
| Diluted shares | 23.5M | 22.6M | 16.7M | 16.7M | 16.7M | 16.7M | 16.4M | 15.2M | 14.9M | 14.5M | 11.0M | 9.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.2M | $50.7M | $46.8M | $28.1M | $29.8M | $35.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $47.3M | $53.3M | $50.0M | $32.0M | $33.5M | $38.4M |
| Total liabilities | $4.0M | $4.3M | $6.9M | $4.8M | $5.1M | $5.0M |
| Shareholders' equity | $43.3M | $49.0M | $43.0M | $27.3M | $28.3M | $33.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology